Empower Cells, Change Lives
Recent News
CCAB And Triumvira Immunologics Announce Triumvira’s License Agreement with University of Toronto for the Discovery of Antibody Drug Development Candidates
AUSTIN, Texas & HAMILTON, Ontario & TORONTO--(BUSINESS WIRE)--The Centre for the Commercialization of Antibodies and Biologics (CCAB) and Triumvira Immunologics, Inc. (Triumvira), announced today a new licensing agreement between the University of Toronto (U...
read moreTriumvira Presents Data on T Cell Antigen Coupler (TAC) Technology at the 6th Annual Immuno-Oncology Summit
TAC technology shows efficacy, safety, and TAC-T cell persistence in preclinical models of liquid and solid tumors AUSTIN, TX, and HAMILTON, ON, August 30, 2018 - Triumvira Immunologics, Inc. (Triumvira), a privately-held biopharmaceutical company focused on designing...
read moreNature Communications Publishes Studies Comparing Triumvira’s T Cell Antigen Coupler (TAC) Technology with CAR T Cell Therapy
Efficacy of Engineered T Cells can be Uncoupled from Toxicities Observed with CAR T Cell Therapy AUSTIN, TX, and HAMILTON, ON, August 3, 2018 – Triumvira Immunologics, Inc., (Triumvira) a privately-held biopharmaceutical company focused on designing safe and more...
read more